QPPV.COM KNOWLEDGE ASSESSMENT

Drug-Induced QT Prolongation: Cardiac Safety Assessment in Clinical Development and Pharmacovigilance

Test your understanding of the concepts covered by Drug-Induced QT Prolongation: Cardiac Safety Assessment in Clinical Development and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 At the aggregate pharmacovigilance level, which pattern would be most concerning?

A single incomplete report of palpitations with no temporal information Multiple reports showing consistent temporal association, recurrent QT prolongation or serious ventricular arrhythmias, and possible dose, exposure or interaction relationships Reports limited to mild dizziness with no cardiac findings A cluster of cases occurring only in untreated controls

Question 2 of 10 Which finding would most strongly support a pharmacological exposure-response relationship for QTc?

A single isolated QTc increase occurring before treatment Reproducible, concentration-dependent QTc changes that are larger at supratherapeutic exposure and occur near peak concentration Different QTc correction methods used for different treatment groups A QTc increase observed only during an episode of severe hypokalaemia with no exposure data

Question 3 of 10 Why can replicate ECG measurements be particularly valuable when evaluating small QTc changes?

They eliminate the influence of heart rate They reduce random measurement variability and improve precision They prove that any observed change is treatment-related They replace the need for a predefined measurement methodology

Question 4 of 10 A development team selects the QT correction formula after reviewing which formula produces the most favourable treatment result. What is the principal methodological concern?

Correction methods are interchangeable at all heart rates The correction method should be prespecified and scientifically justified because formulas behave differently, particularly at heart-rate extremes Only Bazett correction is acceptable in clinical development A correction formula is unnecessary when placebo is included

Question 5 of 10 Why is a placebo or comparator important in population-level QTc analysis?

It guarantees that all QTc measurements are technically accurate It helps distinguish a drug-related effect from circadian, procedural, physiological and measurement variability It eliminates the need to assess drug exposure It demonstrates that any QTc change is caused by the investigational treatment

Question 6 of 10 What is the central contribution of the 2022 E14/S7B Questions and Answers to QT assessment?

It makes QTc the sole determinant of proarrhythmic risk It supports integration of clinical and nonclinical evidence rather than reliance on a single test It removes the need for exposure assessment It establishes that hERG inhibition alone predicts clinical torsade de pointes

Question 7 of 10 Why should population-level QT analysis and individual-subject review both be performed during development?

They answer identical questions and are interchangeable Individual review identifies treatment-group means, while population analysis diagnoses individual causality Population analysis evaluates a coherent treatment-related effect, while individual review examines clinically important findings and patient-specific susceptibility Only individual review is relevant because mean QTc cannot be interpreted

Question 8 of 10 Which conclusion would best support a determination of low proarrhythmic risk?

One negative hERG assay despite absent clinical exposure data No QTc prolongation in one subject, despite concerning arrhythmic events in others A coherent totality of evidence including reassuring nonclinical findings, adequate exposure assessment, no meaningful QTc effect at relevant exposures and no concerning arrhythmic events A QTc result below a threshold, regardless of electrolytes or concomitant medicines

Question 9 of 10 What is the primary purpose of predefined QTc outlier criteria in a clinical development programme?

To establish causality for every flagged participant To identify findings requiring further review in a consistent, prospective manner To replace population-level ECG analysis To diagnose torsade de pointes without reviewing clinical events

Question 10 of 10 Which pairing correctly describes the principal focus of ICH E14 and ICH S7B?

E14: nonclinical toxicology; S7B: post-marketing case processing E14: clinical QT/QTc and proarrhythmic assessment; S7B: nonclinical delayed ventricular repolarisation assessment E14: liver injury assessment; S7B: renal injury assessment E14: manufacturing controls; S7B: pharmacovigilance signal detection

QPPV.com

Drug-Induced QT Prolongation: Cardiac Safety Assessment in Clinical Development and Pharmacovigilance

Cookie Settings